Part of Age-Related Macular Degeneration
1 published article · Updated continuously
20 trials tracked for Geographic Atrophy: 6 in phase 3 or 4 and 5 with published results. The most-cited published study has 462 citations.
Showing the 20 most-cited and recently-updated of 20 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Avacincaptad pegol has demonstrated a statistically significant reduction in geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) 3. Additionally, multiple time-point analyses of the mean rate of growth (slope) for GA area using FAF showed significant results at both 3 time points (p=0.0064) and 5 time points (p=0.0165) 5.
APL-2 demonstrated a statistically significant reduction in the total area of GA lesions at month 12 (p=0.0004) and month 24 (p<0.0001) across two separate trials [2, 4]. One trial also showed a significant mean change in the total area of GA lesions through month 24 (p=0.0007) 4.
Avacincaptad pegol did not show statistically significant changes in best corrected visual acuity (BCVA) at 24 months (p=0.58) 5 or other visual acuity measures including low luminance BCVA (p=0.8405) 3.
AI synthesis of 4 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
